By suggesting IGF-I as a molecule that bridges inflammation and muscle wasting and by recognising decreased physical performance as a crucial contributor to sarcopenia, we provide clinicians with additional tools to measure and combat sarcopenia in this population. This evidence concerns the gene IGF1 and sarcopenia.